IBIO vs AKRO

Analysts rate Akero Therapeutics, Inc.

(AKRO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Akero Therapeutics, Inc.

(AKRO) delivered a total return of +100. 0%, compared to -99. 8% for iBio, Inc. (IBIO). Over 10 years, the gap is even starker: AKRO returned +198. 3% versus IBIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.

(AKRO) is the lower-risk stock at 0. 35β versus iBio, Inc. 's 2. 03β — meaning IBIO is approximately 482% more volatile than AKRO relative to the S&P 500. On balance sheet safety, Akero Therapeutics, Inc. (AKRO) carries a lower debt/equity ratio of 5% versus 24% for iBio, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: iBio, Inc.

grew EPS 73. 1% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Akero Therapeutics, Inc.

(AKRO) is the more profitable company, earning 0. 0% net margin versus -45. 9% for iBio, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKRO leads at 0. 0% versus -46. 5% for IBIO. At the gross margin level — before operating expenses — IBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Akero Therapeutics, Inc.

(AKRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), +198. 3% 10Y return). iBio, Inc. (IBIO) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AKRO: +198. 3%, IBIO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IBIO is a small-cap high-growth stock; AKRO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.